Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer: A Randomized Clinical Trial.


Journal

JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861

Informations de publication

Date de publication:
01 May 2019
Historique:
pubmed: 5 4 2019
medline: 11 2 2020
entrez: 5 4 2019
Statut: ppublish

Résumé

Most patients with advanced-stage cancer develop impairment and pain-driven functional losses that jeopardize their independence. To determine whether collaborative telerehabilitation and pharmacological pain management improve function, lessen pain, and reduce requirements for inpatient care. The Collaborative Care to Preserve Performance in Cancer (COPE) study was a 3-arm randomized clinical trial conducted at 3 academic medical centers within 1 health care system. Patient recruitment began in March 2013 and follow-up concluded in October 2016. Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer. Participants were randomly assigned to the (1) control arm, (2) telerehabilitation arm, or (3) telerehabilitation with pharmacological pain management arm. All patients underwent automated function and pain monitoring with data reporting to their care teams. Participants in arms 2 and 3 received 6 months of centralized telerehabilitation provided by a physical therapist-physician team. Those in arm 3 also received nurse-coordinated pharmacological pain management. Blinded assessment of function using the Activity Measure for Postacute Care computer adaptive test, pain interference and average intensity using the Brief Pain Inventory, and quality of life using the EQ-5D-3L was performed at baseline and months 3 and 6. Hospitalizations and discharges to postacute care facilities were recorded. The study included 516 participants (257 women and 259 men; mean [SD] age, 65.6 [11.1] years), with 172 randomized to 1 of 3 arms. Compared with the control group, the telerehabilitation arm 2 had improved function (difference, 1.3; 95% CI, 0.08-2.35; P = .03) and quality of life (difference, 0.04; 95% CI, 0.004-0.071; P = .01), while both telerehabilitation arms 2 and 3 had reduced pain interference (arm 2, -0.4; 95% CI, -0.78 to -0.09; P = .01 and arm 3, -0.4; 95% CI, -0.79 to -0.10; P = .01), and average intensity (arm 2, -0.4; 95% CI, -0.78 to -0.07; P = .02 and arm 3, -0.5; 95% CI, -0.84 to -0.11; P = .006). Telerehabilitation was associated with higher odds of home discharge in arms 2 (odds ratio [OR], 4.3; 95% CI, 1.3-14.3; P = .02) and 3 (OR, 3.8; 95% CI, 1.1-12.4; P = .03) and fewer days in the hospital in arm 2 (difference, -3.9 days; 95% CI, -2.4 to -4.6; P = .01). Collaborative telerehabilitation modestly improved function and pain, while decreasing hospital length of stay and the requirement for postacute care, but these outcomes were not enhanced with the addition of pharmacological pain management. ClinicalTrials.gov identifier: NCT01721343.

Identifiants

pubmed: 30946436
pii: 2729683
doi: 10.1001/jamaoncol.2019.0011
pmc: PMC6512772
doi:

Substances chimiques

Analgesics 0

Banques de données

ClinicalTrials.gov
['NCT01721343']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

644-652

Subventions

Organisme : NCI NIH HHS
ID : R01 CA163803
Pays : United States
Organisme : National Cancer Institute
ID : R01 CA163803
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Can J Nurs Res. 2005 Dec;37(4):138-54
pubmed: 16541823
JAMA. 2014 Jul 16;312(3):240-8
pubmed: 25027139
Arch Phys Med Rehabil. 2008 Jun;89(6):1046-53
pubmed: 18503798
JAMA. 2009 May 27;301(20):2099-110
pubmed: 19470987
J Am Med Dir Assoc. 2018 Apr;19(4):348-354.e4
pubmed: 29371127
Phys Ther. 2007 Apr;87(4):385-98
pubmed: 17311888
Health Aff (Millwood). 2014 Oct;33(10):1793-800
pubmed: 25288424
Acta Oncol. 2015 May;54(5):618-28
pubmed: 25752965
JAMA Intern Med. 2016 Apr;176(4):484-93
pubmed: 26954564
J Med Econ. 2017 Feb;20(2):193-199
pubmed: 27676291
J Gen Intern Med. 2017 Apr;32(4):404-410
pubmed: 28243873
J Gen Intern Med. 2009 Jun;24(6):733-8
pubmed: 19418100
Phys Ther. 2017 Nov 1;97(11):1094-1102
pubmed: 29077945
Arch Phys Med Rehabil. 2008 Nov;89(11):2146-55
pubmed: 18996244
J Urol. 1998 Mar;159(3):888-92
pubmed: 9474176
Contemp Clin Trials. 2018 Jan;64:254-264
pubmed: 28887068
J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9
pubmed: 27112310
Arch Phys Med Rehabil. 2017 Feb;98(2):203-210
pubmed: 27592401
J Pain Symptom Manage. 2013 May;45(5):811-21
pubmed: 23017624
Arch Phys Med Rehabil. 2004 Apr;85(4):661-6
pubmed: 15083444
JAMA. 2014 Aug 27;312(8):809-16
pubmed: 25157724
Health Aff (Millwood). 2015 Apr;34(4):601-8
pubmed: 25847642
J Clin Oncol. 2018 Jan 1;36(1):76-82
pubmed: 29068784
J Am Med Dir Assoc. 2012 Jul;13(6):569.e1-7
pubmed: 22572555
J Thorac Oncol. 2009 May;4(5):595-601
pubmed: 19276834
Med Decis Making. 2015 Oct;35(7):912-26
pubmed: 25997920
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
JAMA. 2010 Jul 14;304(2):163-71
pubmed: 20628129
Nurs Res. 2001 Jul-Aug;50(4):222-32
pubmed: 11480531
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Support Care Cancer. 2013 Jul;21(7):1893-9
pubmed: 23411998
JAMA. 2003 May 14;289(18):2387-92
pubmed: 12746362
J Pain. 2003 Feb;4(1):2-21
pubmed: 14622723
Am Heart J. 2005 Mar;149(3):434-43
pubmed: 15864231
Oncologist. 2011;16(11):1649-57
pubmed: 21948693
J Clin Oncol. 2014 Dec 20;32(36):4149-54
pubmed: 25403222
Phys Med Rehabil Clin N Am. 2017 Feb;28(1):1-17
pubmed: 27912990
J Natl Cancer Inst. 2013 May 1;105(9):634-42
pubmed: 23482657
Health Qual Life Outcomes. 2014 May 05;12:66
pubmed: 24886430
Arch Phys Med Rehabil. 2006 Aug;87(8):1033-42
pubmed: 16876547
Am J Lifestyle Med. 2009 Jul 1;3(1 Suppl):508-548
pubmed: 20161372
J Orthop Sports Phys Ther. 2016 Sep;46(9):756-67
pubmed: 27494055
Thorax. 2016 Jun;71(6):493-500
pubmed: 27030578
Rhinology. 2019 Apr 1;57(2):110-116
pubmed: 30175337
Arch Intern Med. 2006 Nov 27;166(21):2314-21
pubmed: 17130383
J Clin Oncol. 2008 Jun 1;26(16):2621-9
pubmed: 18509174
Biometrics. 1975 Mar;31(1):103-15
pubmed: 1100130
Arch Phys Med Rehabil. 2012 Jul;93(7):1153-60
pubmed: 22749314
Gen Hosp Psychiatry. 2014 Nov-Dec;36(6):599-606
pubmed: 25130518

Auteurs

Andrea L Cheville (AL)

Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota.

Timothy Moynihan (T)

Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Jeph Herrin (J)

Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.

Charles Loprinzi (C)

Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Kurt Kroenke (K)

Center for Implementing Evidence-Based Practice, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH